Vale SA vs GeneDx Holdings Corp — how do they compare? Vale SA trades at $14.37 (market cap $62.26B), while GeneDx Holdings Corp trades at $81.98 (market cap $2.32B). The key difference: Vale SA is far larger — about 26.8× GeneDx Holdings Corp's market cap, and Vale SA pays a 8.12% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| VALE | WGS | |
|---|---|---|
Market Cap | $62.26B | $2.32B |
Sector | Basic Materials | Technology |
52-Week High | $17.82 | $167.51 |
52-Week Low | $9.71 | $34.51 |
Enterprise Value | $78.50B | $2.35B |
Dividend Yield | 8.12% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.
Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.
Trailing returns across standard periods
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →